Seragen, Inc.
Records under this name other than patents Seragen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,992,108 | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor Formerly held Term ended Term ended Jan 31, 2023 · From the USPTO record | Term ended | Term ended Jan 31, 2023 | From the USPTO record |
| US 6,316,404 | Treating NIDDM with RXR agonists Formerly held Term ended Term ended Dec 22, 2020 · From the USPTO record | Term ended | Term ended Dec 22, 2020 | From the USPTO record |
| US 6,228,862 | Treating NIDDM with RXR agonists Formerly held Term ended Term ended May 11, 2019 · From the USPTO record | Term ended | Term ended May 11, 2019 | From the USPTO record |
| US 6,320,074 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors Formerly held Term ended Term ended Oct 27, 2018 · From the USPTO record | Term ended | Term ended Oct 27, 2018 | From the USPTO record |
| US 6,521,633 | Treating NIDDM with RXR agonists Formerly held Term ended Term ended Feb 20, 2018 · From the USPTO record | Term ended | Term ended Feb 20, 2018 | From the USPTO record |
| US 7,655,699 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors Formerly held Lapsed on the fee record Ended Feb 2, 2018 · From the USPTO record | Lapsed on the fee record | Ended Feb 2, 2018 | From the USPTO record |
| US 6,074,636 | Method of using cell surface receptor targeted molecules for the treatment of viral diseases Formerly held Term ended Term ended Jun 13, 2017 · From the USPTO record | Term ended | Term ended Jun 13, 2017 | From the USPTO record |
| US 6,043,279 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors Formerly held Term ended Term ended Feb 12, 2017 · From the USPTO record | Term ended | Term ended Feb 12, 2017 | From the USPTO record |
| US 6,022,950 | Hybrid molecules having translocation region and cell-binding region Term ended Term ended Feb 8, 2017 · From the USPTO record | Term ended | Term ended Feb 8, 2017 | From the USPTO record |
| US 6,028,052 | Treating NIDDM with RXR agonists Formerly held Term ended Term ended Sep 17, 2016 · From the USPTO record | Term ended | Term ended Sep 17, 2016 | From the USPTO record |